Acrivon Therapeutics, Inc. Contracts & Agreements
26 Contracts & Agreements
- Business Finance (6 contracts)
- Business Operations (1)
- Human Resources (9)
- Intellectual Property (2)
- Uncategorized (8)
- Fourth Amendment to OncoSignature Companion Diagnostic Agreement, by and between the Registrant and Akoya Biosciences, Inc., dated October 25, 2024 (Filed With SEC on November 13, 2024)
- Form of Letter Agreement, dated April 8, 2024, by and among Acrivon Therapeutics, Inc. and each of the persons party thereto (Filed With SEC on April 9, 2024)
- Form of Letter Agreement, dated April 8, 2024, by and among Acrivon Therapeutics, Inc. and each of the persons party thereto (Filed With SEC on April 9, 2024)
- Form of Registration Rights Agreement (Filed With SEC on April 9, 2024)
- Form of Securities Purchase Agreement, dated April 8, 2024, by and among Acrivon Therapeutics, Inc. and each of the purchasers as party thereto (Filed With SEC on April 9, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on April 9, 2024)
- Third Amendment to OncoSignature Companion Diagnostic Agreement, by and between the Registrant and Akoya Biosciences, Inc., dated December 4, 2023 (Filed With SEC on March 28, 2024)
- Second Amendment to OncoSignature Companion Diagnostic Agreement, by and between Acrivon Therapeutics, Inc. and Akoya Biosciences, Inc., dated June 19, 2023 (Filed With SEC on March 28, 2024)
- Amended and Restated Executive Employment Agreement, dated May 30, 2023, by and between the Registrant and Kristina Masson (Filed With SEC on March 28, 2024)
- Description of registrants securities (Filed With SEC on March 28, 2024)
- Second Amendment to OncoSignature Companion Diagnostic Agreement, by and between Acrivon Therapeutics, Inc. and Akoya Biosciences, Inc., dated June 19, 2023 (Filed With SEC on August 11, 2023)
- Amended and Restated Employment Agreement, dated as of May 30, 2023, by and between Acrivon Therapeutics, Inc. and Kristina M. Masson (Filed With SEC on June 5, 2023)
- Contract of Employment, dated as of May 30, 2023, by and between Acrivon AB and Kristina M. Masson (Filed With SEC on June 5, 2023)
- Non-Employee Director Compensation Policy (Filed With SEC on November 3, 2022)
- 2022 Employee Stock Purchase Plan (Filed With SEC on November 3, 2022)
- 2022 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award... (Filed With SEC on November 3, 2022)
- Form of Underwriting Agreement (Filed With SEC on November 3, 2022)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated November 9, 2021 (Filed With SEC on October 17, 2022)
- Employment Offer Letter Agreement, dated October 5, 2020, and Letter Amendment to Employment Offer Letter Agreement, dated August 5, 2022, by and between the Registrant and Eric... (Filed With SEC on October 17, 2022)
- Employment Offer Letter Agreement, by and between the Registrant and Erick Gamelin, dated February 26, 2021 (Filed With SEC on October 17, 2022)
- Executive Employment Agreement, by and between the Registrant and Peter Blume-Jensen, dated October 5, 2020 (Filed With SEC on October 17, 2022)
- Patent License Agreement, by and between the Registrant and Peter Blume-Jensen, dated April 12, 2018 (Filed With SEC on October 17, 2022)
- OncoSignature Companion Diagnostic Agreement, by and between the Registrant and Akoya Biosciences, Inc., dated June 17, 2022 (Filed With SEC on October 17, 2022)
- License Agreement, by and between the Registrant and Eli Lilly and Company, dated January 27, 2021 (Filed With SEC on October 17, 2022)
- Form of Indemnification Agreement with Executive Officers and Directors (Filed With SEC on October 17, 2022)
- 2019 Stock Incentive Plan and Forms of Stock Option Agreement and Notice of Exercise (Filed With SEC on October 17, 2022)
